See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
oad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report For: ALDX
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is looking strong going into the second quarter of 2016. Not only does this company have a good cash position, but it also it has a strong pipeline as well. As a result, one key analyst has decided to weigh in on the firm and where it stands to go from here.
Janney Montgomery Scott reiterated a Buy rating and $25 fair value on expected utility for aldehyde trapping in topical and systemic indications.
The company reported 2015 year-end cash of $27.6 million. That, combined with the $3.6 million-potential-remaining credit facility, is expected to fund operations through 2017, not taking into account expenses for new studies.
Phase 2 data for uveitis is on track for the second quarter of 2016, and for Sjogren-Larsson (SLS) for second quarter or third quarter.
Allergic conjunctivitis (AC) and uveitis are two different forms of ocular inflammation. Aldeyra’s proprietary aldehyde-trap NS2 has proven efficacious in conjunctivitis, and the company is waiting on the uveitis data to define a path forward in ophthalmology. In Janney’s view, positive data from the uveitis trial in the second quarter is important to bolster expectations for the broad applicability of NS2 for inflammation, as well as specifically in the eye.
In the report, Janney detailed:
Aldeyra reported a 64% year over year increase in operating expenses. The increased expenses are largely attributable to increased R&D from the 3 phase 2 trials. Once the systemic formulation of the drug is available, the company intends to expand into other inflammatory indications, which could potentially further add to the expenses. As mentioned above, we model significant new expenses for clinical development. Therefore, we model equity financings in the third quarter of 2016 and third quarter of 2017. These assumptions may be overly aggressive due to management comments that the company may partner the ocular indications. Our valuation also assumes retention of ownership for all 3 indications, AC, uveitis, and SLS, at this time.
Shares of Aldeyra closed Friday at $4.24, with a consensus analyst price target of $21.20 and a 52-week trading range of $3.39 to $11.79.
By Chris Lange
Source – 24/7 Wall Street
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news